1. Lawrence B. Finer, Ph.D., and Mia R. Zolna, M.P.H. Declines in Unintended Pregnancy in the United States, 2008–2011, N Engl J Med 2016; 374:843-852 March 3, 2016 DOI: 10.1056/NEJMsa1506575
  2. Jain R, Muralidhar S. Contraceptive methods: needs, options and utilization. J Obstet Gynaecol India. 2011;61(6):626-634. doi:10.1007/s13224-011-0107-7
  3. Contraceptive use in the United States by demographics. Guttmacher Institute. Published May 28, 2021. Accessed April 18, 2022
  4. FastStats – contraceptive use. Centers for Disease Control and Prevention. Published November 10, 2020. Accessed April 18, 2022
  5. Products – data briefs – number 327 – December 2018. Centers for Disease Control and Prevention. Published February 14, 2019. Accessed April 18, 2022
  6. Hoffman S, Maynard R, eds. Kids Having Kids: Economic Costs and Social Consequences of Teen Pregnancy, 2nd ed. Washington: Urban Institute Press; 2008
  7. Grundy E, Kravdal Ø. Do short birth intervals have long-term implications for parental health? Results from analyses of complete cohort Norwegian register data. J Epidemiol Community Health. 2014;68(10):958-964. doi:10.1136/jech-2014-204191
  8. Bailey MJ, Hershbein B, Miller AR. The opt-in revolution? contraception and the gender gap in wages. NBER. Published March 23, 2012. Accessed April 18, 2022
  9. Bailey MJ, Malkova O, Norling J. DO FAMILY PLANNING PROGRAMS DECREASE POVERTY? EVIDENCE FROM PUBLIC CENSUS DATA. CESifo Econ Stud. 2014;60(2):312-337. doi:10.1093/cesifo/ifu011
  10. Fifty years of family planning … – brookings institution. Accessed April 18, 2022
  11. Stover, J., Ross, J. How Increased Contraceptive Use has Reduced Maternal Mortality. Matern Child Health J 14, 687–695 (2010).
  12. Access to contraception. ACOG. Accessed April 18, 2022
  13. Britton, Laura E. PhD, RN; Alspaugh, Amy MSN, RN, CNM; Greene, Madelyne Z. PhD, RN; McLemore, Monica R. PhD, MPH, RN, FAAN CE: An Evidence-Based Update on Contraception, AJN, American Journal of Nursing: February 2020 – Volume 120 – Issue 2 – p 22-33 doi: 10.1097/01.NAJ.0000654304.29632.a7
  14. The ESHRE Capri Workshop Group, Screening before and during the use of oral contraceptives and hormone replacement therapy, Human Reproduction, Volume 15, Issue 2, February 2000, Pages 485–492,
  15. CDC – how to be reasonably certain a woman is not pregnant – US SPR – Reproductive Health. Centers for Disease Control and Prevention>. Published February 1, 2017. Accessed April 18, 2022
  16. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65(No. RR-3):1–104. DOI:
  17. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404. doi:10.1016/j.contraception.2011.01.021
  18. Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc., 2018
  19. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;(3):CD004695. Published 2005 Jul 20 doi:10.1002/14651858.CD004695.pub2
  20. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive [published correction appears in Contraception. 2004 Feb;69(2):175]. Contraception. 2003;68(2):89-96. doi:10.1016/s0010-7824(03)00141-0
  21. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-2266. doi:10.1056/NEJMoa1111840
  22. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813. Published 2014 Mar 3. doi:10.1002/14651858.CD010813.pub2
  23. Mona Eng P, Seeger JD, Loughlin J, Oh K, Walker AM. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Contraception. 2007;75(2):101-107. doi:10.1016/j.contraception.2006.08.011
  24. Allen, Rebecca. Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use. In: Post TW, ed. UpToDate. UpToDate 2022. Accessed June 6,2020.
  25. Emans SJ, Grace E, Woods ER, Smith DE, Klein K, Merola J. Adolescents’ compliance with the use of oral contraceptives. JAMA. 1987;257(24):3377-3381.
  26. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996;174(2):628-632. doi:10.1016/s0002-9378(96)70440-4
  27. Akerlund M, Røde A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol. 1993;100(9):832-838. doi:10.1111/j.1471-0528.1993.tb14309.x
  28. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;(1):CD003987. Published 2014 Jan 29. doi:10.1002/14651858.CD003987.pub5
  29. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet. 2003;362(9379):185-191. doi:10.1016/S0140-6736(03)13907-4
  30. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94(3):483-489. doi:10.1161/01.cir.94.3.483
  31. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890. Published 2009 Aug 13. doi:10.1136/bmj.b2890
  32. Solymoss S. Risk of venous thromboembolism with oral contraceptives. CMAJ. 2011;183(18):E1278-E1279. doi:10.1503/cmaj.111614
  33. Tepper NK, Whiteman MK, Zapata LB, Marchbanks PA, Curtis KM. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception. 2016;94(6):630-640. doi:10.1016/j.contraception.2016.04.016
  34. Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia. 2000;20(3):155-156. doi:10.1046/j.1468-2982.2000.00035.x
  35. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054. Published 2015 Aug 27. doi:10.1002/14651858.CD011054.pub2
  36. Lobo RA, Skinner JB, Lippman JS, Cirillo SJ. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril. 1996;65(6):1100-1109.
  37. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323(20):1375-1381. doi:10.1056/NEJM199011153232003
  38. Ortizo R, Lee SY, Nguyen ET, Jamal MM, Bechtold MM, Nguyen DL. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017;29(9):1064-1070. doi:10.1097/MEG.0000000000000915
  39. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1-580.e9. doi:10.1016/j.ajog.2017.02.002
  40. Karlsson T, Johansson T, Höglund J, Ek WE, Johansson Å. Time-Dependent Effects of Oral Contraceptive Use on Breast, Ovarian, and Endometrial Cancers. Cancer Res. 2021;81(4):1153-1162. doi:10.1158/0008-5472.CAN-20-2476
  41. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017;377(23):2228-2239. doi:10.1056/NEJMoa1700732
  42. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-1621. doi:10.1016/S0140-6736(07)61684-5
  43. Brady PC, Missmer SA, Laufer MR. Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate. J Pediatr Adolesc Gynecol. 2017;30(3):422-424. doi:10.1016/j.jpag.2016.12.002
  44. Pyra M, Heffron R, Mugo NR, et al. Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS. 2015;29(17):2353-2359. doi:10.1097/QAD.0000000000000827
  45. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48(3):484-489. doi:10.1111/j.1528-1167.2007.00997.x
  46. Palmery M, Saraceno A, Vaiarelli A, Carlomagno G. Oral contraceptives and changes in nutritional requirements. Eur Rev Med Pharmacol Sci. 2013;17(13):1804-1813.
  47. Davis AR, Kroll R, Soltes B, Zhang N, Grubb GS, Constantine GD. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril. 2008;89(5):1059-1063. doi:10.1016/j.fertnstert.2007.05.012
  48. FSRH Guideline (January 2019) Combined Hormonal Contraception. BMJ Sex Reprod Health 2019;45:1–93.doi:10.1136/bmjsrh-2018-CHC
  49. Shapiro K, Bombatch C, Garrett S, et al. RxPrep course book: 2022 Naplex course book. 2022:667-669.
  50. Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(4):1-66. Published 2016 Jul 29. doi:10.15585/mmwr.rr6504a1
  51. Camila [package insert.] Pomona, NY: Barr Laboratories, Inc; 2002
  52. Slynd [package insert]. Florham Park, NJ: Exeltis USA, Inc; 2019
  53. Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception. 2018;97(6):478-489. doi:10.1016/j.contraception.2018.01.010
  54. Napolitano A, Zanin R, Palma F, et al. Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraception. Eur J Contracept Reprod Health Care. 2016;21(2):168-175. doi:10.3109/13625187.2015.1079610
  55. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280(6):533-538. doi:10.1001/jama.280.6.533
  56. Shoupe D, Horenstein J, Mishell DR Jr, Lacarra M, Medearis A. Characteristics of ovarian follicular development in Norplant users. Fertil Steril. 1991;55(4):766-770.
  57. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678-700. doi:10.1016/j.contraception.2016.04.014
  58. Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69(2):89-97. doi:10.1016/j.contraception.2003.09.002
  59. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-2032. doi:10.1056/NEJMoa013202
  60. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131-1137. doi:10.1093/jnci/91.13.1131
  61. Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(4):CD003552. Published 2013 Apr 30. doi:10.1002/14651858.CD003552.pub4
  62. Camila [package insert.] Pomona, NY: Barr Laboratories, Inc; 2002
  63. TWIRLA Camila [package insert.] Grand Rapids, MI: Corium International, Inc; 2020
  64. Ortho Evra [package insert.] Titusville, NJ: Janssen Ortho, LLC; 2018
  65. Van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168-174. doi:10.1016/j.contraception.2005.03.005
  66. Devineni D, Skee D, Vaccaro N, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol. 2007;47(4):497-509. doi:10.1177/0091270006297919
  67. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril. 2002;77(2 Suppl 2):S27-S31. doi:10.1016/s0015-0282(01)03263-0
  68. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002;77(2 Suppl 2):S19-S26. doi:10.1016/s0015-0282(01)03264-2
  69. Goa KL, Warner GT, Easthope SE. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Treat Endocrinol. 2003;2(3):191-206. doi:10.2165/00024677-200302030-00005
  70. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95(2):130-139. doi:10.1016/j.contraception.2016.10.005
  71. Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care. 2007;12(3):240-247. doi:10.1080/13625180701440180
  72. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16(3):469-475. doi:10.1093/humrep/16.3.469
  73. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-223. doi:10.1016/j.contraception.2006.03.022
  74. Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception. 2006;73(5):488-492. doi:10.1016/j.contraception.2005.11.003
  75. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74(6):451-457. doi:10.1016/j.contraception.2006.07.004
  76. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005;20(2):557-562. doi:10.1093/humrep/deh604
  77. Nuvaring [package insert]. Whitehouse Station, NJ: Merck and Co, Inc. 2001
  78. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39(3):233-242. doi:10.2165/00003088-200039030-00005
  79. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100(3):585-593. doi:10.1016/s0029-7844(02)02124-5
  80. Annovera [package insert]. New York, NY: Population Counsel; 2018
  81. Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005;106(3):473-482. doi:10.1097/01.AOG.0000175144.08035.74
  82. Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800-808. doi:10.1097/AOG.0b013e3182a5ec6b
  83. Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93-100. doi:10.1016/j.contraception.2012.09.015
  84. Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod. 2002;17(10):2594-2599. doi:10.1093/humrep/17.10.2594
  85. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44(1):32-38. doi:10.1210/jcem-44-1-32
  86. DEPO-PROVERA- [package insert] Kalamazoo, MI: Pharmacia Corporation; 2002
  87. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41(5 Suppl):381-390.
  88. Shelton JD, Halpern V. Subcutaneous DMPA: a better lower dose approach. Contraception. 2014;89(5):341-343. doi:10.1016/j.contraception.2013.10.010
  89. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7-17. doi:10.1016/j.contraception.2009.02.005
  90. Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell DR Jr. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception. 2010;81(6):487-495. doi:10.1016/j.contraception.2010.01.021
  91. Gupta N, O’Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol. 2001;14(2):71-76. doi:10.1016/s1083-3188(01)00074-2
  92. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82(6):1580-1586. doi:10.1016/j.fertnstert.2004.04.064
  93. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86(5):1466-1474. doi:10.1016/j.fertnstert.2006.05.024
  94. Ulrich CM, Georgiou CC, Snow-Harter CM, Gillis DE. Bone mineral density in mother-daughter pairs: relations to lifetime exercise, lifetime milk consumption, and calcium supplements. Am J Clin Nutr. 1996;63(1):72-79. doi:10.1093/ajcn/63.1.72
  95. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74(2):90-99. doi:10.1016/j.contraception.2006.03.010
  96. Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121(3):593-600. doi:10.1097/AOG.0b013e318283d1a1
  97. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol. 2009;114(4):786-794. doi:10.1097/AOG.0b013e3181b76bea
  98. Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol. 2011;117(1):41-47. doi:10.1097/AOG.0b013e318202ac23
  99. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10(2):181-202. doi:10.1016/0010-7824(74)90073-0
  100. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception. 1998;58(5):283-288. doi:10.1016/s0010-7824(98)00110-3
  101. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599-604. doi:10.1097/AOG.0000000000000690
  102. Nexplanon- [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2015
  103. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646-1653. doi:10.1016/j.fertnstert.2008.02.140
  104. Villas-Boas J, Vilodre LC, Malerba H, Pontremoli Salcedo M, Foresti Jiménez M, El Beitune P. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period. Eur J Obstet Gynecol Reprod Biol. 2016;202:51-54. doi:10.1016/j.ejogrb.2016.04.025
  105. Han L, Jensen JT. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?. Obstet Gynecol Clin North Am. 2015;42(4):683-698. doi:10.1016/j.ogc.2015.07.007
  106. Floyd JL, Beasley AD, Swaim LS, Turrentine MA, Nijjar JB. Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism. Obstet Gynecol. 2020;135(6):1275-1280. doi:10.1097/AOG.0000000000003760
  107. Morrell KM, Cremers S, Westhoff CL, Davis AR. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year. Contraception. 2016;93(3):263-265. doi:10.1016/j.contraception.2015.11.005
  108. Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3:9. Published 2018 Jul 23. doi:10.1186/s40834-018-0064-y
  109. Buhling KJ, Zite NB, Lotke P, Black K; INTRA Writing Group. Worldwide use of intrauterine contraception: a review. Contraception. 2014;89(3):162-173. doi:10.1016/j.contraception.2013.11.011
  110. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14-21. doi:10.1016/j.contraception.2017.10.003
  111. Diedrich JT, Zhao Q, Madden T, Secura GM, Peipert JF. Three-year continuation of reversible contraception. Am J Obstet Gynecol. 2015;213(5):662.e1-662.e6628. doi:10.1016/j.ajog.2015.08.001
  112. Trussell J, Hassan F, Lowin J, Law A, Filonenko A. Achieving cost-neutrality with long-acting reversible contraceptive methods. Contraception. 2015;91(1):49-56. doi:10.1016/j.contraception.2014.08.011
  113. Paragard [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; 2014
  114. De la Cruz D, Cruz A, Arteaga M, Castillo L, Tovalin H. Blood copper levels in Mexican users of the T380A IUD. Contraception. 2005;72(2):122-125. doi:10.1016/j.contraception.2005.02.009
  115. Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015;91(4):280-283. doi:10.1016/j.contraception.2015.01.011
  116. Schwarz EB, Lewis CA, Dove MS, et al. Comparative Effectiveness and Safety of Intrauterine Contraception and Tubal Ligation [published online ahead of print, 2022 Feb 23]. J Gen Intern Med. 2022;1-8. doi:10.1007/s11606-022-07433-4
  117. Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol. 2017;130(6):1226-1236. doi:10.1097/AOG.0000000000002307
  118. Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol. 2019;134(4):791-800. doi:10.1097/AOG.0000000000003463
  119. Guleria K, Agarwal N, Mishra K, Gulati R, Mehendiratta A. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer?. J Obstet Gynaecol Res. 2004;30(3):181-187. doi:10.1111/j.1447-0756.2004.00182.x
  120. Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv. 1996;51(12 Suppl):S42-S51. doi:10.1097/00006254-199612000-00014
  121. Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002;187(6):1699-1708. doi:10.1067/mob.2002.128091
  122. Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol. 2014;123(3):585-592. doi:10.1097/AOG.0000000000000144
  123. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999
  124. Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1):50.e1-50.e508. doi:10.1016/j.ajog.2014.07.025
  125. Godfrey EM, Whiteman MK, Curtis KM. Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review. Contraception. 2013;87(5):567-575. doi:10.1016/j.contraception.2012.08.005
  126. Lowe RF, Prata N. Hemoglobin and serum ferritin levels in women using copper-releasing or levonorgestrel-releasing intrauterine devices: a systematic review. Contraception. 2013;87(4):486-496. doi:10.1016/j.contraception.2012.09.025
  127. Mirena [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc; 2000
  128. Kyleena [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals, INC; 2000
  129. Liletta [package insert]. Parsippany, NJ: Actavis Pharma, Inc; 2015
  130. Skyla [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc; 2000
  131. Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet. 1983;8(2):95-136. doi:10.2165/00003088-198308020-00001
  132. Sivin I, Lähteenmäki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception. 1997;55(2):81-85. doi:10.1016/s0010-7824(96)00276-4
  133. Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92(1):10-16. doi:10.1016/j.contraception.2015.04.006
  134. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49(1):56-72. doi:10.1016/0010-7824(94)90109-0
  135. O’Brien PA, Kulier R, Helmerhorst FM, Usher-Patel M, d’Arcangues C. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception. 2008;77(5):318-327. doi:10.1016/j.contraception.2007.12.011
  136. Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol. 2017;146(1):34-38. doi:10.1016/j.ygyno.2017.04.006
  137. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception. 2017;95(1):17-39. doi:10.1016/j.contraception.2016.10.006
  138. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Positive Testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease in IUD Users. J Womens Health (Larchmt). 2015;24(5):354-359. doi:10.1089/jwh.2015.5190
  139. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356(9234):1013-1019. doi:10.1016/S0140-6736(00)02699-4
  140. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol. 1991;78(2):291-298.
  141. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. 1994;61(1):70-77. doi:10.1016/s0015-0282(16)56455-3
  142. Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med. 2002;47(11):881-885.
  143. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol. 2004;190(1):50-54. doi:10.1016/j.ajog.2003.07.021
  144. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota [published correction appears in Am J Obstet Gynecol. 2021 Oct;225(4):434]. Am J Obstet Gynecol. 2018;218(6):622.e1-622.e10. doi:10.1016/j.ajog.2018.02.017
  145. Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217-222. doi:10.1097/OLQ.0b013e31823e68fe
  146. Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015;91(4):274-279. doi:10.1016/j.contraception.2015.01.007
  147. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82(1):41-55. doi:10.1016/j.contraception.2010.02.011
  148. Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122(6):1214-1221. doi:10.1097/01.AOG.0000435452.86108.59
  149. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility–follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92. doi:10.1016/j.contraception.2006.09.010
  150. Stoddard AM, Xu H, Madden T, Allsworth JE, Peipert JF. Fertility after intrauterine device removal: a pilot study. Eur J Contracept Reprod Health Care. 2015;20(3):223-230. doi:10.3109/13625187.2015.1010639
  151. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41-47. doi:10.5812/ijem.4158

Get Started with Scripted

Please complete the following fields

A text message will be sent to your phone to begin your Intake Form

Answer these quick questions and we'll text you a link to your intake form.